Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/29/2025

Intractable Hiccups Treatment Guidelines

First-Line Treatment

  • The American Academy of Pediatrics recommends chlorpromazine as a dopamine receptor antagonist, likely interrupting the hiccup reflex arc at the medullary level, with a dosing of 25-50 mg orally three to four times daily, or 25-50 mg intramuscularly if oral therapy fails after 2-3 days, and notes that it requires monitoring for dystonic reactions, orthostatic hypotension, and QTc prolongation 1

Second-Line Alternatives

  • The National Comprehensive Cancer Network recommends metoclopramide, with randomized controlled trial evidence, at a dosing of 10-20 mg orally or IV every 4-6 hours, particularly useful when gastroparesis or gastric outlet obstruction contributes to hiccups, and notes that it requires monitoring for dystonic reactions 2
  • The National Comprehensive Cancer Network suggests metoclopramide as a prokinetic and dopamine antagonist, with dual benefit, and notes that it is particularly useful when gastroparesis or gastric outlet obstruction contributes to hiccups 3
  • The National Comprehensive Cancer Network recommends monitoring for dystonic reactions with metoclopramide, and having diphenhydramine available 4
  • The National Comprehensive Cancer Network suggests haloperidol as an alternative dopamine antagonist, used in palliative care settings, at a dosing of 0.5-2 mg orally or IV every 4-6 hours, and notes that it carries a risk of extrapyramidal symptoms and QTc prolongation 2

Critical Monitoring Points

  • The American Academy of Pediatrics recommends monitoring for QTc prolongation with all antipsychotic agents, especially with concurrent medications that prolong QT interval 1
  • The National Comprehensive Cancer Network recommends watching for extrapyramidal symptoms with all dopamine antagonists, and treating with diphenhydramine 25-50 mg if dystonia occurs 4
  • The National Comprehensive Cancer Network suggests assessing for underlying causes requiring specific treatment, such as GERD, CNS lesions, metabolic abnormalities, and gastric distension 3
  • The National Comprehensive Cancer Network recommends considering nebulized lidocaine as a last resort for truly refractory cases, though assessing aspiration risk first 5

Treatment of Intractable Hiccups with Identified Underlying Causes

Identifying and Addressing Underlying Causes

  • Metabolic abnormalities, such as electrolyte disturbances, should be identified and addressed before initiating treatment, as they can contribute to intractable hiccups 6
  • Area postrema syndrome, characterized by intractable hiccups with nausea and vomiting, may indicate MOG encephalomyelitis and should be considered in the differential diagnosis 6

Hiccup Management with Dopamine Antagonists

Medication Considerations

  • The National Comprehensive Cancer Network recommends avoiding the use of multiple dopamine antagonists concurrently, such as chlorpromazine, metoclopramide, and haloperidol, to avoid excessive dopamine blockade 7
  • In elderly patients, consider using 5 mg olanzapine, as recommended by the National Comprehensive Cancer Network, due to its potential benefits in managing hiccups 7

Chlorpromazine for Intractable Hiccups

Adverse Effects

  • The American Academy of Child and Adolescent Psychiatry notes that anticholinergic effects, including sedation and potential memory deficits, are associated with chlorpromazine use, with elderly patients showing heightened sensitivity 8

Baclofen for Intractable Hiccups

Efficacy

  • In patients with intractable hiccups—particularly those whose symptoms are dominated by regurgitation or belching—baclofen produced an initial response in about 60 % of participants in a small randomized, placebo‑controlled trial, indicating moderate efficacy (Level B evidence) 9.

Safety

  • Compared with conventional neuroleptic agents, baclofen was associated with fewer adverse effects during long‑term treatment, suggesting a more favorable safety profile for chronic use (Level B evidence) 9.